Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kiniksa Pharmaceuticals reports robust Q2 growth and strategic initiatives

Kiniksa Pharmaceuticals delivered a strong Q2 performance with significant revenue growth driven by ARCALYST sales and strategic initiatives. The company's focus on disease awareness and patient base expansion bodes well for future growth.
While challenges such as managing expenses and addressing operational complexities persist, Kiniksa's solid financial position and market opportunities position it favorably for sustained growth and value creation.
Overall, Kiniksa Pharmaceuticals' Q2 earnings call highlights a mix of strong performance, strategic strengths, operational challenges, and growth opportunities, signaling a dynamic and evolving landscape for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of -20.45% and 14.86%, respectively, for the quarter ended December 2021.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates

– ARCALYST ® (rilonacept) net revenue of $18.7 million in Q4 2021 and $38.5 million in 2021 – – ARCALYST collaboration achieved profitability in Q4 2021 – – ARCALYST full-year 2022 net revenue expected to be $115 - $130 million – – Strategic collaboration with Huadong Medicine to develop and commercialize ARCALYST and mavrilimumab in the Asia Pacific Region (excluding Japan) – – Conference call and webcast scheduled for 8:30 am ET today –

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

– Collaboration includes rights to develop and commercialize ARCALYST ® and mavrilimumab in the Asia Pacific Region (excluding Japan) –

Kiniksa Pharmaceuticals and Huadong Medicine Announce Strategic Collaboration

HAMILTON, Bermuda, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 22, 2022, at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2021 financial results and corporate update.

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on February 22, 2022

HAMILTON, Bermuda, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 1:30 p.m. Eastern Time.

Kiniksa Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 150.6% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 151% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Can the Stock Really Move This High?

Kiniksa (KNSA) reports that the phase III portion of mavrilimumab???s phase II/III study for COVID-related ARDS did not meet the primary efficacy endpoint.

Kiniksa (KNSA) COVID-19 Study for ARDS Fails to Meet Main Goal

Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) is trading lower Tuesday morning after the company announced the Phase 3 trial of mavrilimumab in COVID-19-related ARDS did not meet the primary efficacy endpoint. Mavrilimumab is an investigational fully human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha.

Why Kiniksa Pharmaceuticals Stock Is Falling Today

HAMILTON, Bermuda, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced that the Phase 3 portion of the Phase 2/3 trial of mavrilimumab in COVID-19-related acute respiratory syndrome (ARDS) did not meet the primary efficacy endpoint. Mavrilimumab is an investigational fully human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFRα).

Kiniksa Announces Results from Phase 3 Trial of Mavrilimumab in COVID-19-Related ARDS

Kiniksa Pharmaceuticals, Ltd. (KNSA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Could Find Support Soon, Here's Why You Should Buy the Stock Now

KNSA is progressing slowly but steadily with its programs.

Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel

HAMILTON, Bermuda, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November 30, 2021 at 12:10 p.m. Eastern Time.

Kiniksa Pharmaceuticals to Present at Evercore ISI 4th Annual HealthCONx Conference

The consensus price target hints at a 137.5% upside potential for Kiniksa Pharmaceuticals, Ltd. (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Kiniksa Pharmaceuticals, Ltd. (KNSA) Climb 138% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 100.2% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Kiniksa Pharmaceuticals, Ltd. (KNSA) Could Surge 100%: Read This Before Placing a Bet

Kiniksa Pharmaceuticals (KNSA) CEO, Sanj Patel on Q3 2021 Results - Earnings Call Transcript

- Q3 2021 ARCALYST ® (rilonacept) net revenue of $12.1 million - - ARCALYST prescribed by more than 200 physicians for recurrent pericarditis since approval - - Data from Phase 3 trial of mavrilimumab in COVID-19-related ARDS expected in Q1 2022 - - Data from Phase 2b trial of vixarelimab in prurigo nodularis expected in 2H 2022 - - Conference call and webcast scheduled for 8:30 am ET today -

Kiniksa Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Portfolio Execution

HAMILTON, Bermuda, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Monday, November 1, 2021, at 8:30 a.m. Eastern Time to report its third quarter 2021 financial results and recent portfolio execution.

Kiniksa Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 1, 2021

HAMILTON, Bermuda, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 10:40 a.m. Eastern Time.

Kiniksa Pharmaceuticals to Present at 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

Kiniksa has one approved product and multiple late-stage programs. The cash balance is strong and a small revenue stream has started.

Kiniksa: Unexciting, Slow Growth Stock

Kiniksa Pharmaceuticals' (KNSA) CEO Sanj Patel on Q2 2021 Results - Earnings Call Transcript

- Q2 2021 ARCALYST ® (rilonacept) net revenue of $7.7 million with greater than 100 prescribing physicians -

Kiniksa Reports Second Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity

HAMILTON, Bermuda, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, August 10, 2021 at 2:55 p.m. Eastern Time.

Kiniksa Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference

HAMILTON, Bermuda, July 20, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, August 3, 2021 at 8:30 a.m. Eastern Time to report its second quarter 2021 financial results and recent corporate and portfolio activity.

Kiniksa Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 3, 2021

HAMILTON, Bermuda, June 08, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced that the U.S Patent and Trademark Office issued a patent covering methods of using ARCALYST® (rilonacept) in the treatment of recurrent pericarditis.

Kiniksa Announces Issuance of U.S. Patent for Treatment of Recurrent Pericarditis

- Defined regulatory pathway for Phase 3 clinical development of mavrilimumab in multiple indications -

News for Kiniksa Pharmaceuticals Ltd Stock (KNSA)